Illumina, Inc. $ILMN Shares Purchased by Banco Bilbao Vizcaya Argentaria S.A.

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. increased its stake in Illumina by 25.7%, owning 60,160 shares valued at approximately $4.77 million as of the latest SEC filing.
• Illumina's recent quarterly earnings report showed an EPS of $1.19, exceeding the consensus estimate of $1.02, although revenue fell 4.8% compared to the previous year.
• Institutional investors control 89.42% of Illumina's stock, indicating significant institutional interest in the company amidst various upgrades and downgrades from analysts.

Banco Bilbao Vizcaya Argentaria S.A. boosted its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 25.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 60,160 shares of the life sciences company's stock after acquiring an additional 12,295 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Illumina were worth $4,765,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Diversified Trust Co acquired a new position in shares of Illumina during the first quarter worth about $355,000. State of Alaska Department of Revenue lifted its stake in shares of Illumina by 2.5% during the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company's stock worth $1,469,000 after purchasing an additional 445 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Illumina by 4.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 199,176 shares of the life sciences company's stock worth $15,803,000 after purchasing an additional 9,252 shares in the last quarter. Merit Financial Group LLC lifted its stake in shares of Illumina by 344.8% during the first quarter. Merit Financial Group LLC now owns 13,036 shares of the life sciences company's stock worth $1,034,000 after purchasing an additional 10,105 shares in the last quarter. Finally, Citigroup Inc. lifted its stake in shares of Illumina by 13.5% during the first quarter. Citigroup Inc. now owns 150,764 shares of the life sciences company's stock worth $11,962,000 after purchasing an additional 17,985 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Trading Down 0.8%

NASDAQ:ILMN opened at $100.80 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The business's 50-day simple moving average is $97.66 and its 200 day simple moving average is $89.50. The stock has a market cap of $15.49 billion, a price-to-earnings ratio of 12.76, a price-to-earnings-growth ratio of 2.28 and a beta of 1.37.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. During the same quarter in the previous year, the firm posted $0.36 earnings per share. The company's revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of recent research reports. Citigroup cut Illumina from a "hold" rating to a "strong sell" rating and reduced their price objective for the stock from $85.00 to $80.00 in a research note on Wednesday, July 9th. Scotiabank cut Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price objective on the stock. in a research note on Friday, July 11th. Barclays boosted their price objective on Illumina from $85.00 to $90.00 and gave the stock an "underweight" rating in a research note on Friday, August 1st. Robert W. Baird boosted their price objective on Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a research note on Monday, July 28th. Finally, Wall Street Zen cut Illumina from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Seven analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $124.58.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.